Abstract: The present invention relates to a long-lasting medical product for protecting or treating a lesion in the gastrointestinal tract. The medical product includes a protective covering, wherein the medical product upon application at and about the site of the lesion adheres to the gastrointestinal tissue and is capable of remaining at and about the site of the lesion for a time sufficient to allow the lesion to heal or be treated.

Abstract: Described herein are zirconium oxychloride clusters comprising zirconium oxychloride and a basic amino acid. Personal care compositions comprising the same, and methods of making and using the same are also described.

Abstract: Described herein are the use of fluid complex coacervates that produce solid adhesives in situ to anchor medical devices such as catheters in a blood vessel. The anchored devices permit the targeted delivery of bioactive agents. The anchored devices can perform as an embolic agent by reducing or preventing blood flow in the vessel. Additionally, the embolic produced from the solid adhesive produced in situ can also include one or more bioactive agents that can be released in a controlled manner.

Abstract: The present invention relates to a new delivery system for nutritional ingredients (nutraceuticals). These nutritional ingredients are useful for gut and metabolic health in monogastric animals, especially in humans.

Abstract: A hair coloring composition that includes about 5 to 25 wt. % of a first monosaccharide having 2 to 4 carbon atoms, up to about 10 wt. % of a second monosaccharide having 2 to 4 carbon atoms, about 0.1 to 5 wt. % of a surfactant, and about 0.1 to 5 wt. % of a delivery agent, each based on a total weight of the hair coloring composition. A method for coloring hair, that involves applying the hair coloring composition onto the hair, and optionally applying heat to the hair at a dyeing temperature of 30 to 205° C.

Abstract: The present invention is in the field of personal care compositions, in particular compositions comprising antiperspirant actives. The present invention more particularly relates to compositions which do not contain the conventional and well established aluminium based actives, yet exhibit similar efficacy. This is achieved through use of an active which is a complex of a zinc salt with a ? amino acid in an anhydrous carrier.

Abstract: According to the invention there is provided inter alia a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization.

Abstract: The disclosure provides a method of producing a pharmaceutical composition. The method comprises (a) dissolving an active pharmaceutical ingredient (API) in a liquid vehicle to form a liquid medicament; (b) contacting the liquid medicament with a pharmaceutical carrier; (c) contacting the composition comprising the liquid medicament and pharmaceutical carrier with a pharmaceutical coating material to form a liqui-mass composition; and (d) pelletising the liqui-mass composition to form the pharmaceutical composition.

Abstract: The present invention relates to a polyhedral complex, a cosmetic agent having the polyhedral complex formed therein, and a cosmetic composition comprising same, the polyhedral complex comprising: a thixotropic polyhedral structure formed of a plurality of flat-type substances; and a mixture of a functional substance and a solvent accommodated in the polyhedral structure. Furthermore, the present invention relates to a method for manufacturing the cosmetic agent, the method comprising: mixing the plurality of flat-type substances, the functional substance, and the solvent; and high-pressure spraying the mixture, and to a method for stabilizing the functional substance in the cosmetic agent.

Abstract: The present invention relates to solid compositions, preferably in powder or granule form, based on minerals (semi-finished or raw material) and a process for preparing said solid compositions. Furthermore, the present invention relates to solid formulations (final products) and orally disintegrating formulations (final products) containing said solid compositions. Moreover, the present invention relates to a process for preparing said solid formulations and said orally disintegrating formulations. Finally, the present invention relates to the use of said solid compositions or said solid or orally disintegrating formulations in the treatment of disorders or diseases related to or derived from a deficiency of minerals such as magnesium (II), calcium (II), iron (III), zinc (II) and/or iodine. All the compositions or formulations of the present invention are suitable for pediatric subjects, adolescents, athletes, men, women, pregnant women and elderly.

Abstract: The present invention relates to devices and methods for treating prolapsed pelvic organ, cystitis and Atrophy in women. Particularly, the invention relates to drug loaded vaginal support devices and methods wherein the device is inserted in vagina to support as well as release the drug. Specifically the invention relates to a Vaginal Ring Pessary comprising Estrogen in Silicone rubber polymer matrix, which releases drug over a prolonged period of about 180 days. Additionally the invention relates to the method of fabrication of the device and its use in treatment of vaginal atrophy, cystitis and uterovaginal prolapse.

Abstract: A medical device substrate with a coating including a functional layer located on the substrate, with the functional layer including at least one sugar alcohol and being bonded to the substrate directly or indirectly via a functionalization of the sugar alcohol. Alternatively, the functional layer may also include other saccharides, in which case it is essential that polymerization of the saccharides takes place only upon bonding to the substrate. The inventive medical device exhibits reduced platelet adhesion and aggregation.

Abstract: Provided is application of genetically engineered bacteria VNP20009-M in preparation of drugs for preventing and treating lung cancer.

Abstract: A water-dissolvable compressed oral nicotine lozenge is disclosed, the oral nicotine lozenge comprising a first module and a second module, the first and the second modules being fused by compression, the first module being a lozenge module comprising at least one sugar alcohol and the second module being an FDT-module comprising at least one sugar alcohol and nicotine. Also, a method of manufacturing a water-dissolvable compressed oral nicotine lozenge is disclosed.

Abstract: The present application relates to beta-1,3-glucan and uses thereof to modulate immunity in the human body. Also provided are methods for treatment and/or prevention of high cholesterol, diabetes, and allergies. Also provided are methods for treatment and/or prevention of intestinal inflammation.

Abstract: According to the invention, there is provided a pharmaceutically-acceptable composition which is preferably in the form of a spray-dried powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of at least one pharmaceutically-active compound; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a combination of a disaccharide and a polymeric material. Compositions are suitable for, for example, transmucosal drug delivery, including sublingual and nasal delivery. In the case of nasal delivery, said compositions may be loaded into single- or multiple-use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include lactose or trehalose and dextrins (e.g. cyclodextrins or maltodextrins), which may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate.

Abstract: A personal care deodorant and/or antiperspirant product substantially void of any endocrine disrupting chemicals, and a method of making the same. Embodiments of the deodorant include one or more of the following: a skin conditioning agent, an emollient, a nonaqueous viscosity increasing agent, a surfactant/emulsifying agent, an absorbent, a soothing agent, a deodorant agent, a viscosity-controlling agent, and a scent.

Abstract: Chitosan can be coated, e.g., in 0.06 or 0.6 wt. %, over spherical silica, e.g., HYPS, loaded with spinel ferrites of theoretical formula MFe2O4, wherein M is Ni, Cu, Co, and/or Mn, e.g., at 30 wt. %, and cisplatin. Chitosan can be fabricated over Pt or cisplatin) bound CuFe2O4-HYPS and CuFe2O4-HYPS followed by Pt loading. Cisplatin and Pt—CuFe2O4-HYPS-chitosan at 0.025 to 0.5 mg/mL exhibit cytotoxicity against human breast cancer cell line (MCF-7) and human embryonic kidney cells (HEK293), relative to Pt—CuFe2O4-HYPS, with Pt—CuFe2O4-HYPS-chitosan, showing non-significant anti-cancer effects due to mediated Pt release. Pt—CuFe2O4/HYPS and CuFe2O4-HYPS-chitosan-Pt reduced cell viability using a different dose effect. Cisplatin in certain composites was less cytotoxic to HEK293 than MCF7, making the a targeted drug delivery system. Inventive composites may improve multifunctional theranostic applications involving pH stimuli, temperature-based drug release, and diagnosis based treatment such as hyperthermia.

Abstract: The present invention relates generally to glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a spacer containing ((2-oxoethyl)thio)). In an aspect the invention provides oxo-eT linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a ((2-oxoethyl)thio) spacer having the formula (I): wherein: A is a group (C?X)m wherein X is S or O and m is 0 or 1; B is a bond, O, or CH2; and when m is 0, B can also be (C?O); R is a C2-C16 alkylene, C2-C16 heteroakylene, NH—C(?O)—C2-C16 alkylene, or NH—C(?O)—C2-C16 heteroakylene, wherein said alkylene and heteroalkylene are optionally substituted by 1, 2 or 3 groups independently selected from COOR? where R? is selected from H, methyl, ethyl or propyl. The invention further relates to immunogenic compositions comprising such glycoconjugates, and to methods for the preparation and use of such glycoconjugates and immunogenic compositions.

Abstract: One compound (100) according to the present invention contains silicon fine particles having a capability of generating hydrogen or aggregates of the silicon fine particles. The compound that contains the silicon fine particles or the aggregates having a capability of generating hydrogen is capable of generating hydrogen in the body of, for example, an animal that has ingested the compound. For a plant, the compound can be disposed or charged into, for example, moisture (water-containing liquid) or fertilizer to be provided to the plant, to supply the plant with hydrogen generated from the compound.